Latest news with #46thAnnualGlobalHealthcareConference2025
Business Wire
03-06-2025
- Business
- Business Wire
Cerus Corporation to Participate in the Goldman Sachs 46 th Annual Global Healthcare Conference 2025
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that members of the management team are scheduled to present at the Goldman Sachs 46 th Annual Global Healthcare Conference 2025 in Miami, Florida, on Wednesday, June 11, 2025, at 8:40 a.m. Eastern Time. A live webcast of the presentation can be accessed via the Events & Presentation section of Cerus' Investor Relations website at A replay of the webcast will be available on Cerus Investor Relations website shortly after the event for 30 days. ABOUT CERUS Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the U.S. For more information about Cerus, visit and follow us on LinkedIn. INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
Yahoo
02-06-2025
- Business
- Yahoo
BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ('BridgeBio' or the 'Company'), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami, FL on Monday, June 9 at 8:40 am ET. To access the live webcast of BridgeBio's presentation during the fireside chat, please visit the 'Events & Presentations' page within the Investors section of the BridgeBio website at A replay of the webcast will be available on the BridgeBio website for 30 days following the event. About BridgeBio Pharma, Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio's pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit and follow us on LinkedIn, Twitter, Facebook, and YouTube. BridgeBio Media Contact:Bubba Murarka, Executive Vice Presidentcontact@ (650)-789-8220 BridgeBio Investor Contact:Chinmay Shukla, VP Strategic Financeir@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30-05-2025
- Business
- Yahoo
Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025
PRINCETON, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in June. Jefferies Global Healthcare Conference 2025 in New York, NY, on Wednesday, June 4, 2025, at 11:40 a.m. ET Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami, FL, on Tuesday, June 10, 2025, at 2:00 p.m. ET A live audio webcast of each presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at About Amicus Therapeutics Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company's website at and follow on X and LinkedIn. CONTACT: Investors:Amicus TherapeuticsAndrew FaughnanVice President, Investor Relationsafaughnan@ (609) 662-3809 Media:Amicus TherapeuticsDiana MooreHead of Global Corporate Affairs and Communications dmoore@ (609) 662-5079 FOLD–GError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
28-05-2025
- Business
- Business Wire
Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on Tuesday, June 10 at 1:00 p.m. PT / 4:00 p.m. ET in Miami Beach, Florida. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days. About Vir Biotechnology Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.
Business Wire
27-05-2025
- Business
- Business Wire
BAXTER TO Present at Goldman Sachs 46th Annual Global Healthcare Conference 2025
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on Tuesday, June 10, 2025. Joel Grade, Baxter's chief financial officer, is scheduled to present at 10:40 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at and will be available for replay through Sunday, December 7, 2025. About Baxter At Baxter, we are everywhere healthcare happens – and everywhere it is going, with essential solutions in the hospital, physician's office and other sites of care. For nearly a century, our customers have counted on us as a vital and trusted partner. And every day, millions of patients and healthcare providers rely on our unmatched portfolio of connected solutions, medical devices, and advanced injectable technologies. Approximately, 38,000 Baxter team members live our enduring mission: to save and sustain lives. Together, we are redefining how care is delivered to make a greater impact today, tomorrow, and beyond. To learn more, visit and follow us on X, LinkedIn and Facebook.
